Authors: Jian Cheng Minwen Ha Yadi Wang Jing Sun Junchen Chen Yue Wang Chunyan Tong
Publish Date: 2011/11/20
Volume: 138, Issue: 2, Pages: 231-238
Abstract
The SNP Asn118Asn C → T in codon 118 of ERCC1 was detected using an AllGlo™ Probebased realtime PCR kit The shortterm clinical outcomes were evaluated by measuring complete and partial responses CR and PR whereas progressionfree survival PFS and overall survival OS were determined to indicate longterm outcomesThe allelic frequencies of the ERCC1 codon 118 were found to be 606 C/C 331 C/T and 63 T/T respectively Overall the CR and PR to cisplatinbased treatment were 331 Notably the response rate of patients carrying an ERCC1 118 C/C allele was more than twofold higher than that of patients with a C/T or T/T genotype 95 confidence interval CI 1065–3910 P = 0032 Correspondingly the longterm median PFS and OS of patients carrying the ERCC1 118 C/C allele were significantly longer than those of patients carrying a C/T or T/T allele P 001 Besides positive correlation was observed between the differentiation status and tumor staging as well as the C/C genotypeOur results suggest that this polymorphism of ERCC1 at codon 118 is associated with patient response to cisplatinbased chemotherapy in treatments of latestage NSCLC Moreover by assaying this SNP in blood cells the ERCC1 codon 118 may represent a valuable biomarker in developing individualized treatments for NSCLC patients
Keywords: